watch
XenoPort, Inc.

XenoPort, Inc.

Sector: Pharmaceutical Preparations Region: CA, United States


: | Nasdaq: XNPT


Similar to: Recordati SpA, Hutchison China MediTech Ltd., Sanofi

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company's first product gabapentin enacarbil which is known as Horizant in United States and Regnite in Japan, is developed for the treatment of moderate-to-severe primary restless legs syndrome in adults. GlaxoSmithKline Plc holds commercialization rights and certain development rights for Horizant in the United States. Astellas Pharma, Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. The XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. The company's pipeline of products candidates includes potential treatments for patients with Postherpetic Neuralgia, Spasticity and Parkinson's disease. XenoPort was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on May 19, 1999 and is headquartered in Santa Clara, CA.

News & Analysis

You may also be interested in: